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Abstract
Background: Generalized Anxiety Disorder (GAD) is under-investigated in people living with HIV/AIDS from subSaharan Africa. In part, this is due to paucity of culturally appropriate measures for GAD which are psychometrically
robust. This study aimed to evaluate the reliability, factorial structure, and validity of Swahili version of the 7-item GAD
questionnaire (GAD-7) among adults living with HIV.
Study design: Descriptive cross-sectional study.
Methods: 450 adults receiving comprehensive care from an HIV specialized clinic in Kilifi County, coastal Kenya, were
consecutively recruited. Swahili versions of GAD-7, Patient Health Questionnaire (PHQ-9) and a 12-item HIV stigma
scale were administered alongside measures of psychosocial and health-related characteristics. Internal consistency,
test–retest reliability, factorial structure, convergent validity, and discriminant validity of Swahili GAD-7 were examined
using Cronbach’s alpha (α), intra-class correlation coefficient (ICC), Confirmatory Factor Analysis (CFA), Pearson’s correlation, and analysis of covariance (ANCOVA), respectively.
Results: Internal consistency of Swahili GAD-7 was good, α = 0.82 (95% CI 0.78, 0.85). Its test–retest reliability (2 weeks
apart) was acceptable, ICC = 0.70 (95% CI 0.55, 0.81). A confirmatory analysis of a one-factor solution indicated an
excellent fit to the hypothesized structure (RMSEA = 0.00 [95% confidence interval 0.00, 0.05], CFI = 1.00, TLI = 1.00).
Multi-group CFA substantiated factorial invariance for sex and age for the one-factor structure of Swahili GAD-7.
Scores of GAD-7, Swahili version, significantly correlated with those of PHQ-9 (r = 0.73; p < 0.001) and the HIV stigma
scale (r = 0.36; p < 0.001) suggesting good convergent validity. Statistically significant differences were observed
between participants on first-line antiretroviral therapy compared to those on second-line treatment (F [1, 441] = 5.55,
p = 0.02) indicative of good discriminant validity of Swahili GAD-7.
Conclusion: GAD-7 Swahili version retained its original unidimensional latent structure with good psychometric
properties among adults living with HIV from Kilifi, Kenya. It can be used to identify symptoms of GAD in similar
research settings. However, to confidently identify those in need of mental health treatment or referral services in HIV
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primary care clinics, more research on the validity of Swahili GAD-7 is needed especially its discriminant validity and
diagnostic accuracy at different cut-off scores.
Keyword: Psychometric properties, Factor analysis, Swahili GAD-7, HIV/AIDS, Adults, Kenya

Introduction
Generalized anxiety disorder (GAD) is one of the most
common mental disorders and a significant contributor
to the global burden of disease [1]. It is characterized
by excessive anxiety and worry about events or activities that are difficult to control [2]. In the general population, the estimated lifetime prevalence of GAD ranges
from 0.4 to 5.7% [3]. In primary healthcare (PHC) settings, prevalence of GAD symptoms ranges from 3.7 to
14.8% [4], and GAD accounts for over half of anxiety
disorders seen in these settings [5]. Among people living with HIV/AIDS (PLWHA) attending primary care
clinics, high prevalence of GAD symptoms has been
reported from high-income settings at 23% [6] and
over 30% [7, 8] from low- and middle-income countries
(LMICs). This high prevalence of GAD symptoms in
PLWHA may result from reaction to initial diagnosis of
HIV or recurring and escalating anxiety symptoms in
response to disease progression.
Generalized Anxiety Disorder is a debilitating condition. It significantly impairs an individual’s healthrelated quality of life [9, 10], and it influences self-care,
help seeking behaviour, and interpersonal functioning
(family and social) [11, 12]. GAD increases propensity for adverse health behaviour such as smoking and
sedentary lifestyle [13] and is strongly associated with
comorbid psychiatric disorders, major depressive disorder being the commonest [14]. Among PLWHA,
GAD is a risk factor for non-adherence to antiretroviral therapy [15]. The economic burden of GAD in terms
of lost work productivity (indirect costs) and costs of
medical services (direct costs) has also been found to
be considerable [16, 17].
Despite being highly prevalent among PLWHA and
impairing, in comparison to other mental disorders,
GAD has received less attention with respect to media,
research and public health efforts [4, 13, 18]. Furthermore, this emotional disorder remains under-diagnosed
and under-treated in primary care settings of most
countries [13, 19]. Previous research has revealed general challenges to the identification and treatment of
disabling mental disorders in PHC settings of LMICs.
These include: a lack of time in busy PHC settings [20],
inadequate knowledge related to symptoms and management of mental illnesses among PHC staff [20, 21], poor
integration of mental health services in PHC [20, 22] and
scarcity of specialized mental health personnel [21, 23].

In part, the inattention to GAD in LMICs may also
be due to the paucity of culturally sensitive and psychometrically robust measures [24]. The 7-item GAD scale
(GAD-7), which was developed in a Western setting,
screens and measures severity of GAD [18], but has limited validation in LMICs. For instance, in sub-Saharan
Africa (SSA), to the best of our knowledge, only one
study has attempted to validate a local version of GAD-7
(Shona version) for use in PHC settings in Zimbabwe
[24], although not exclusively among PLWHA. This local
version of GAD-7 (at an optimal cutoff ≥ 10) showed
good performance characteristics, i.e., Cronbach alpha
of 0.87, with sensitivity of 89% (95% confidence interval:
81–94%) and specificity of 73% (95% confidence interval:
65–80%) against the Structured Clinical Interview of the
Diagnostic and Statistical Manual of Mental DisordersIV (SCID), a gold standard tool for the diagnosis of GAD.
In view of availing more locally validated GAD measures in LMICs, specifically SSA where both GAD and
HIV are highly prevalent [7, 8, 25], this study evaluated the psychometric properties of a Swahili version of
GAD-7 among adults living with HIV from rural Kilifi,
Kenya. Specific aims were to describe: (i) the internal
consistency; (ii) test–retest reliability; (iii) factorial structure; (iv) convergent validity; and (v) discriminant validity
of Swahili GAD-7.

Methods
Study setting and participants

This work is part of data collected from a larger crosssectional study looking at different outcomes in PLWHA,
including health-related quality of life and mental health.
The cross-sectional study was conducted at the Center for
Geographic Medicine Research (CGMR), located in Kilifi
County, between 20th February and 15th April 2018. The
centre is within Kilifi County Hospital, the main referral
hospital. In Kilifi County, prevalence of HIV in adults is
estimated as 4.5% [26]. Participants were adults living
with HIV attending an HIV specialized clinic at the Kilifi
County Hospital. To be included in the study, they had to
be 18 to 60 years old, with confirmed HIV-positive status,
on antiretroviral therapy, and able to comprehend and/or
communicate in the national language (Kiswahili) since
this language was used during administration of all study
instruments and asking for consent. We did not include
elderly individuals (above 60 years) living with HIV
because of the increased likelihood of illnesses associated
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with advancing age, which may have an impact on quality of life [27], an outcome of interest in the larger study.
In total, 512 participants visiting the HIV clinic for their
appointments were approached to participate, 44 of
whom declined participation, whereas 18 were excluded
because they were over 60 years of age (n = 11) or could
not comprehend or communicate in Kiswahili (n = 7).
The remaining 450 adults living with HIV participated in
the study.
Study instruments
Sociodemographic and health‑related characteristics

In the larger study, sociodemographic, health and treatment history forms were administered in a face-to-face
interview in private rooms at the HIV clinic. We only
present variables relevant to the present analyses. These
include sociodemographic data on age, sex, marital status, level of education, employment, and information
about participant antiretroviral regimen, World Health
Organization (WHO) disease staging [28], and presence
of any current chronic medical illness (they have been
made aware of by their clinician).
Clinical history

A clinical record form was used to extract the following
data from the medical records of recruited participants
at the HIV clinic: antiretroviral regimen (first line versus
second line), viral load (within the last one year), cluster
of differentiation 4 [CD4] cell count, and WHO-based
disease staging. However, we found no recent follow-up
CD4 tests for all the recruited participants during data
extraction. The available CD4 cell count information,
not for all participants, was that when they were being
enrolled into care. From the medical records, there were
major missing data (n = 145) for the most recent viral
load tests of our participants. Therefore, from the clinical
data, we only present information on antiretroviral regimen (first line versus second line) and disease staging.
7‑Item generalized anxiety disorder scale (GAD‑7) [18]

GAD-7, Swahili version, was administered to all study
participants. Using a Likert scale of 0 (not at all) to 3
(nearly every day), participants are asked how often they
have been bothered by problems such as feeling nervous, worrying, or restlessness in the past two weeks.
Total score ranges from 0 to 21. According to the manual,
summated scores of 5–9 indicates mild GAD symptoms,
10–14 indicate moderate GAD symptoms, and a summated score ≥ 15 indicates severe GAD symptoms. Previous research has suggested that the GAD-7 is a valid
screening tool for GAD and for assessing its severity in
clinical practice and research [18].
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9‑Item patient health questionnaire (PHQ‑9) [29]

PHQ-9 screens and provides a measure of severity of
depressive symptoms. It is scored on a Likert scale of 0
(not at all) to 3 (nearly every day).The summated score
ranges between 0 and 27, with a cut-off of 10 generally
accepted as a positive screen for depressive symptoms
[30]. Used among PLWHA in Kenya [31], this measure presented good internal consistency (Cronbach’s
α = 0.78) and acceptable test–retest reliability (intraclass correlation coefficient [ICC] = 0.59). In this study,
its internal consistency was good, α = 0.81 (95% CI 0.78,
0.84).
12‑Item HIV stigma scale [32]

Was used to assess participant perceived HIV-related
stigma under four dimensions of: (i) personalized stigma;
(ii) disclosure concerns; (iii) negative self-image; and (iv)
concerns with public attitudes. Items on this scale are
rated as 1 (strongly disagree), 2 (disagree), 3 (agree), and
4 (strongly agree). Total score ranges between 12 and
48, higher scores indicative of greater level of perceived
HIV-related stigma. In the initial validation conducted in
Sweden, Cronbach’s alpha was > 0.70 [32]. In this study
Cronbach’s alpha was 0.81 (95% CI 0.78, 0.83).
Translations

In line with international guidelines for translation of
tools in health research (https://www.who.int/substance_
abuse/research_tools/translation/en/), all questionnaires
were independently translated from English to Swahili by
two staff members fluent in both languages. Back-translations into English were then done by another independent pair of translators. To ensure content, conceptual,
semantic and idiomatic equivalence of the questionnaires
[33], a committee of HIV researchers (natives of Kenya,
knowledgeable about the Kenyan culture, bilingual and
fluent in both English and Kiswahili) and the translators
then held a harmonization meeting. Discrepancies in the
translations were resolved by consensus. The final versions were obtained following incorporation of changes
resulting from pretesting procedures.
Statistical analysis

Cronbach’s alpha was used to evaluate internal consistency of Swahili GAD-7. ICC assessed test–retest reliability (using data of 60 participants rescreened 2 weeks
following initial assessment). Using structural equation
modelling, confirmatory factor analysis (CFA) with diagonally weighted least squares was used to determine the
factor structure of Swahili GAD-7. An a priori model was
specified, where one factor underlies the item responses
and each item loads onto this unidimensional factor.
The loadings associated with responses from the Swahili
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GAD-7 were then generated. The choice to confirm a
one-factor structure was informed through an exploratory factor analysis (EFA) that checked for a possibility of the posited two-dimensional structure of GAD-7
[34, 35]. We examined the goodness-of-fit between
the hypothesized model and the data using the following fit indices: root mean square error of approximation
[RMSEA], comparative fit index [CFI] and Tucker–Lewis
index [TLI]). Using multiple indices provides a conservative and reliable evaluation of model fitness [36].
Based upon the literature [37–39], fit indices were considered acceptable if RMSEA ≤ 0.08, CFI and TLI ≥ 0.90,
or excellent if RMSEA ≤ 0.06, CFI and TLI ≥ 0.95. Prior
to CFA, we checked for sampling adequacy using Kaiser–Meyer–Olkin (KMO) value and Bartlett’s test of
sphericity. We also examined inter-item correlations
using Kendall tau-b correlation (in view of the ordinal
measurement level of the items of GAD-7). Multi-group
CFA was conducted to determine measurement invariance (configural, metric, and scalar invariance) between
sexes (female versus male) and age groups (young adults
18–35 years versus middle-aged adults 36–60 years) for
the hypothesized unidimensional factor structure of
Swahili GAD-7. We used difference in CFI (ΔCFI), cutoff value ≤ 0.01, to define invariance as this is the most
widely used and empirically best supported criterion
[40–42]. Convergent validity was assessed through correlation of GAD-7 scores with scores of both PHQ-9
and 12-item HIV stigma scale (Pearson’s product correlation). For discriminant validity, independent Student’s
t-test followed by analysis of covariance (ANCOVA) were
used to evaluate whether GAD-7 is sensitive to antiretroviral regimen (first-line versus second-line treatment).
We used antiretroviral regimen as a proxy for perceived
treatment success (switching to second-line treatment
perceived as poor treatment success and expected to be
related to higher GAD-7 scores) because of missing data
on biological markers of disease progression (viral load
or CD4 cell count) from the participant clinical records.
All analyses were conducted using STATA (version 14.0)
statistical software package except test–retest and CFA
analyses which were done on R (version 3.4.1) software.

Results
Participant description

Table 1 summarizes sociodemographic, health and treatment characteristics of study participants by sex. Majority of the study participants were females (79.1%). The
mean age of the 450 recruited participants was 42.7 years
(Standard Deviation [SD] = 9.7). Participants’ median
PHQ-9 score was 3 (Inter-Quartile Range [IQR]: 1—7).
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For perceived HIV-related stigma, mean score was 28.4
(SD = 7.7).
Item characteristics

Table 2 presents the mean (SD) participant scores for
each of the GAD-7 items alongside percentage response
across the ordinal Likert scale options. Of important note
is that responses were distributed across all the Likert
options in the expected direction indicative of no major
ceiling or floor effects.
Tool reliability

Cronbach alpha for the Swahili version of GAD-7
revealed very good internal consistency, α = 0.82 (95%
confidence interval [95% CI] 0.78, 0.85). Table 3 presents
item–total correlations, the correlation of each item with
the rest of the items, inter-item covariance and item
alphas. Test–retest reliability of Swahili GAD-7 as indicated by intra-class correlation coefficient was acceptable, ICC = 0.70 (95% CI 0.55, 0.81).
Factorial structure

Prior to CFA, we examined KMO and Bartlett’s test of
sphericity for sampling adequacy and ran an EFA to
check the possibility of a two-dimensional factorial structure. KMO value was 0.84 while Bartlett’s test of sphericity was highly significant χ2 = 1057.32, p < 0.001. These
results suggested that there were correlations in the
dataset appropriate for factor analysis. Table 4 presents
Kendall’s tau-b inter-item correlation coefficients. The
correlations ranged from r = 0.3 to r = 0.7 and were all
statistically significant at p < 0.001. EFA analysis showed
a clear one-factor structure. The first factor was the only
one with an eigen value above one (2.92) and explained
81.4% of the variance. Figure 1 shows the scree plot of the
eigen values which suggests a one-factor structure best fit
the data.
In CFA, all the GAD-7 Swahili items loaded well on this
one-factor solution (item factor loading ≥ 0.5). Table 2
presents the factor loadings. Goodness-of-fit indices for
the unidimensional factorial structure of Swahili GAD-7
were all excellent (RMSEA < 0.01 [95% CI 0.00, 0.05];
CFI = 1.00; TLI = 1.00).
Measurement invariance across sex and age groups

Multi-group CFA was used to determine the extent to
which the unidimensional factorial structure of Swahili
GAD-7 was invariant across sex (female versus male)
and age groups (young adults versus middle-aged adults).
Overall, this multi-group analysis confirmed sex and age
invariance of Swahili GAD-7.
In a model assuming the same item-factor assignment
across sex and age groups (configural invariance), the
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Table 1 Study participants’ sociodemographic, health, and treatment characteristics by gender
Characteristic

Total sample N = 450

Female n = 356

Male n = 94

Age group
18–24 years

20 (4.4%)

11 (3.1%)

9 (9.6%)

25–35 years

87 (19.3%)

79 (22.2%)

8 (8.5%)

36–49 years

223 (49.6%)

175 (49.2%)

48 (51.1%)

50–60 years

120 (26.7%)

91 (25.6%)

29 (30.9%)

Married/cohabiting

196 (43.6%)

142 (39.9%)

54 (57.5%)

Separated/divorced/widowed

197 (43.8%)

173 (48.6%)

24 (25.5%)

57 (12.7%)

41 (11.5%)

16 (17.0%)

Marital status

Never married
Education
Tertiary

22 (4.9%)

13 (3.7%)

9 (9.6%)

Secondary

66 (14.7%)

42 (11.8%)

24 (25.5%)

Primary

239 (53.1%)

180 (50.6%)

59 (62.8%)

None

123 (27.3%)

121 (34.0%)

2 (2.1%)

Employment
53 (11.8%)

34 (9.6%)

19 (20.2%)

Self-employed

Formally employed

117 (26.0%)

95 (26.7%)

22 (23.4%)

Unemployed

269 (59.8%)

219 (61.5%)

50 (53.2%)

11 (2.4%)

8 (2.3%)

3 (3.2%)

Other
Current chronic medical illnessa
Present

37 (8.2%)

30 (8.4%)

7 (7.5%)

413 (91.8%)

326 (91.6%)

87 (92.6%)

425 (95.3%)

335 (95.2%)

90 (95.7%)

21 (4.7%)

17 (4.8%)

4 (4.3%)

Stage 1

417 (93.7%)

334 (94.9%)

83 (89.3%)

Not present
Antiretroviral regimenb
First line
Second line
WHO disease staging
Stage 2

22 (4.9%)

14 (4.0%)

8 (8.6%)

Stage 3

3 (0.7%)

2 (0.6%)

1 (1.1%)

Stage 4

3 (0.7%)

2 (0.6%)

1 (1.1%)

All variables had complete data except for antiretroviral regimen (4 missing observations) and WHO disease staging (5 missing observations)
a

Based on client self-reporting as informed by their clinician

b

All the 21 participants on second-line medication were initially started on first line

one-factor solution of Swahili GAD-7 fitted the data well
in both groups (Table 5). This is an indication that similar latent constructs have been measured in the groups
hence the one-factor measurement model is acceptable
for both sexes and age groups.
Assuming same item-factor assignment but also constraining factor loadings to equivalence across sex and
age groups (metric invariance), all the goodness-of-fit
indices for the one-factor solution of Swahili GAD-7
were excellent (Table 5). Comparing this metric invariance model to the least stringent configural invariance model, ΔCFI was < 0.001 and 0.009 for sex and age
groups, respectively.

Assuming same item-factor assignment, but also constraining factor loadings and item intercepts to equivalence across sex and age groups (scalar invariance), all
goodness-of-fit indices for the one-factor solution of
Swahili GAD-7 were also excellent (Table 5). Comparing
this scalar invariance model to the less restrictive metric
invariance model, ΔCFI was < 0.001 and 0.008 for sex and
age groups, respectively.
Evaluating all the goodness-of-fit indices and ΔCFI
indicated that the scalar invariance model fitted the data
best for sex group while metric invariance model fitted
the data best for age group.
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Table 2 Swahili GAD-7 item descriptive and CFA factor loadings
Item code

Item descriptiona

Item descriptive
Item scoreb

% responses in each category
0

1

2

3

Factor
loadingsc

GAD1

Feeling nervous, anxious or on edge

0.36 (0.65)

71.3

22.9

3.8

2.0

0.76

GAD2

Not being able to stop or control worrying

0.24 (0.57)

81.3

14.0

3.6

1.1

0.74

GAD3

Worrying too much about different things

0.39 (0.73)

71.7

20.9

3.8

3.6

0.77

GAD4

Trouble relaxing

0.43 (0.80)

71.8

18.4

4.9

4.9

0.53

GAD5

Being so restless that it is hard to sit still

0.30 (0.65)

78.0

16.9

2.5

2.7

0.47

GAD6

Becoming easily annoyed or irritable

0.61 (0.83)

55.4

33.7

5.4

5.6

0.51

GAD7

Feeling afraid as if something awful might happen

0.33 (0.60)

72.4

23.6

2.4

1.6

0.66

GAD-7 Total item score

2.66 (3.35)

NA

NA

NA

NA

NA

NA

NA

NA

NA

NA

GAD-7 Total item score (median [IQR])

1 (0—4)

IQR: inter-quartile range
NA: not applicable
0-not at all, 1-several days, 2-more than half the days, 3-nearly everyday
a

Item requires respondents to consider the past 2 weeks

b

Item score presented as mean (SD)

c

Item loadings to the one-factor structure using confirmatory factor analysis

Table 3 Item correlation, inter-item covariance and item
alphas
Item

Item–test
correlation

Item–rest
correlation

Average interitem covariance

Alphaa

GAD1

0.78

0.68

0.37

0.78

GAD2

0.76

0.65

0.38

0.79

GAD3

0.78

0.68

0.38

0.78

GAD4

0.65

0.51

0.42

0.81

GAD5

0.60

0.44

0.44

0.82

GAD6

0.61

0.46

0.43

0.82

GAD7

0.70

0.58

0.40

0.80

The displayed values are for standardized items
a

The item alpha presented is if the respective item is deleted

Convergent and discriminant validity

Scores of GAD-7, Swahili version, highly and moderately
correlated with those of PHQ-9 (r = 0.73; p < 0.001) and

12-item HIV stigma scale (r = 0.36; p < 0.001), respectively. These patterns of results support convergent
validity of Swahili GAD-7. Raw mean scores on Swahili
version of GAD-7 were significantly higher among study
participants on second-line antiretroviral treatment compared to those on first-line treatment (4.24 versus 2.60;
p = 0.03). Using ANCOVA adjusted for age, sex and presence of any chronic medical illness, the observed difference remained statistically significant (F [1, 441] = 5.55,
p = 0.02) suggestive of good discriminant validity of Swahili GAD-7.

Discussion
We sought to investigate the psychometric properties and factorial structure of Swahili version of GAD-7
among adults living with HIV from Kilifi. To the best
of our knowledge, this is the first study from SSA that
explores psychometric properties of GAD-7 exclusively

Table 4 Kendall tau-b inter-item correlation coefficient
GAD1
GAD1

GAD2

GAD3

GAD4

GAD5

GAD6

GAD7

1.00

GAD2

0.69

1.00

GAD3

0.54

0.60

1.00

GAD4

0.36

0.34

0.34

1.00

GAD5

0.29

0.35

0.34

0.50

1.00

GAD6

0.32

0.30

0.37

0.26

0.27

1.00

GAD7

0.44

0.40

0.40

0.33

0.26

0.36

All correlations were statistically significant at p < 0.001

1.00
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Fig. 1 Scree plot of the eigen value

among PLWHA. In summary, we found that Swahili
version of GAD-7, had good internal consistency and
acceptable test–retest reliability. Swahili GAD-7 retained
unidimensional latent structure where all items loaded
well on a one-factor solution and this model was invariant across sex and age groups. The scale also presented
good convergent and discriminant validity.
The Swahili GAD-7 had Cronbach alpha of 0.82 which
suggests that it is internally consistent. Rating scales are
considered to have acceptable-to-excellent internal consistency if Cronbach’s alpha ranges between 0.70 and
0.95 [43]. Our finding corroborates previously reported
findings of good internal consistency of GAD-7 from its
original validation study [18], and other validation studies involving a general population from Germany [44],
psychiatric sample from Portugal and United States [34,
45], pregnant women from Peru [46], and PHC population with high HIV burden from Zimbabwe [24].
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The stability of GAD-7 between evaluations over time
is rarely investigated globally with no data from SSA.
Adding to the overall limited body of knowledge about
test–retest reliability of GAD-7, we report that Swahili GAD-7 is stable for evaluations done 2 weeks apart
in SSA context. Spitzer et al. [18] in the original validation of GAD-7, reported a high test–retest reliability of
GAD-7 (ICC = 0.83). Sousa, et al. [45] investigating stability of a Portuguese version of GAD-7 for evaluations
carried out 1 week apart also found that the scale had
good test–retest reliability (item ICC range = 0.56 to
0.93).
This is the first study that reports on factorial structure of GAD-7 among PLWHA and specifically from
SSA context. We first checked for sampling adequacy
(using KMO value and Bartlett’s test of sphericity), which
we found was appropriate for factor analysis. The interitem correlation coefficients also ranged from moderate to strong and were all highly significant. We then
ran EFA which showed a clear one-factor structure of
the Swahili GAD-7. With this supporting background,
we proceeded to conduct CFA. We found that Swahili
GAD-7 retained the unidimensional latent structure.
All items loaded well to a one-factor solution (factor
loadings ≥ 0.5) with excellent goodness-of-fit indices
(RMSEA, CFI, TLI), as recommended in the literature
[36, 44]. Measurement invariance (i.e., configural, metric,
and scalar) was explored across both sex and age groups.
We note that majority of the study participants were
females. This high recruitment of females is expected
since women in SSA, compared to men, are more likely
to access available treatment [47]. Nevertheless, all the
fit indices were excellent and ΔCFI, for defining invariance, was within the recommended cut-off [40, 41]. This

Table 5 Goodness of fit indices for multi-group confirmatory factor analysis of unidimensional factorial structure
of Swahili GAD-7
RMSEAa (95% CI)

TLIb

CFIb

ΔCFIc

Reference
model

1. Configural invariance

0.000 (0.000–0.018)

1.028

1.000

–

–

2. Metric invariance

0.000 (0.000–0.038)

1.012

1.000

< 0.001

1

3. Scalar invariance

0.000 (0.000–0.031)

1.015

1.000

< 0.001

2

1. Configural invariance

0.000 (0.000–0.036)

1.017

1.000

–

–

2. Metric invariance

0.025 (0.000–0.057)

0.989

0.991

0.009

1

3. Scalar invariance

0.032 (0.000–0.059)

0.982

0.983

0.008

2

Invariance model
Sex

Age

RMSE root mean square error of approximation, 95% CI–95% confidence interval, TLI Tucker–Lewis index, CFI-comparative fit index; Δ–change in
a
b
c

Acceptable fit ≤ 0.08, excellent fit ≤ 0.06

Acceptable fit ≥ 0.90, excellent fit ≥ 0.95

Acceptable cut-off to detect invariance ≤ 0.01
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result suggests that the unidimensional Swahili GAD-7 is
invariant across both sex and age groups. Previous validation studies, from different regions, have also reported
acceptable-to-excellent goodness-of-fit indices for the
unidimensional structure of GAD-7 [44–46, 48] and its
factorial invariance across both sex and age [44], but also
across language-preference groups [49].
We examined convergent validity through correlation
of scores from Swahili GAD-7 with those from PHQ-9
and the 12-item HIV stigma scale (measures of theoretically related constructs). We found good convergent
validity of Swahili GAD-7 with these two measures. Our
finding is consistent with findings from previous studies
that investigated correlations of scores of GAD-7 with
those of theoretically related construct measures such as
measures of psychiatric morbidity [34, 49, 50], quality of
life [45, 49] and disability [48].
We investigated discriminant validity by comparing mean GAD-7 scores of participants on first-line and
second-line antiretroviral therapy. We used participant
antiretroviral regimen as a proxy marker for perceived
treatment success (those switching to second-line treatment perceiving poor treatment success expected to be
related to higher GAD-7 scores). A change from first-line
to second-line is a major step and is usually indicated
because of toxicity or resistance to first-line treatment
[51]. Whatever the case, there is an underlying treatment failure which may trigger anxiety symptoms when a
patient is informed. Adjusting for sociodemographic and
health factors, we found statistically significant group
differences suggestive of good discriminant validity of
Swahili GAD-7. García-Campayo, et al. [48] also found
Spanish GAD-7 to have good discriminant validity while
comparing mean scores of participants with a prior diagnosis of clinical GAD versus that of a control group.
Study limitations

Despite the study strengths in terms of sample size and
methodological approaches to evaluating reliability, factorial structure and validity of Swahili GAD-7, it is not
without limitations. We recruited participants from one
primary care centre, thus these findings may not be generalizable to other settings or regions. We used a proxy
indicator—antiretroviral regimen—to examine discriminant validity. Future studies involving PLWHA should
confirm our finding by investigating for group differences on GAD-7 scores using either or both standard
biomarkers of disease progression (viral load and/or CD4
cell count). We did not explore the diagnostic accuracy
of Swahili GAD-7, therefore we recommend a separate
study in this or similar setting, exploring the sensitivity
and specificity of this measure at different cut-off values, using a diverse sample of PLWHA, to identify the
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optimal cut-off score for identifying those in need of
mental health treatment or referral services in HIV clinical settings.

Conclusion
Our findings suggest that Swahili GAD-7 is a unidimensional scale with good psychometric properties among
adults living with HIV from Kilifi, Kenya. It can be used
to identify symptoms of GAD in similar research settings.
However, to confidently identify those in need of mental
health treatment or referral services in HIV primary care
clinics, more research on the validity of Swahili GAD-7
is needed especially its discriminant validity and diagnostic accuracy at different cut-off scores. We recommend
use of a diverse sample of PLWHA from this or similar
settings.
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